Review Reports
- Mengqi Zhao and
- Philip Lazarus *
Reviewer 1: Anonymous Reviewer 2: Anonymous Reviewer 3: María Ángeles Peña Fernández
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe study is technically interesting and provides useful mechanistic data, but several issues should be addressed to strengthen the manuscript. The main concern is that the in vitro recombinant-microsome findings are sometimes extended toward clinical/pharmacogenetic implications without direct human validation. The authors themselves acknowledge the need for clinical studies and the possibility that additional hepatic CYP enzymes contribute to metabolism.
comments
- The study relies entirely on recombinant CYP-overexpressing microsomes, human liver microsomes (HLM), and human intestinal microsomes (HIM). Although the findings strongly implicate CYP2C9, there are no human pharmacokinetic or clinical genotype–phenotype data to demonstrate that the observed differences in CYP2C9 activity actually translate into altered Δ8-THC exposure in vivo. Therefore, statements regarding dosage adjustment and interindividual pharmacokinetic variability should be moderated.
- The authors conclude that CYP2C9 is the major enzyme for intestinal 11′-hydroxylation but acknowledge that other enzymes may contribute substantially to hepatic metabolism. Since the hepatic clearance of Δ8-THC is clinically important, screening additional CYP isoforms and/or using selective chemical or antibody inhibition in HLM would substantially strengthen the mechanistic conclusion.
- The unbound fraction of Δ8-THC was not experimentally determined; instead, fu values reported for Δ9-THC were used as surrogates. Because the calculated unbound kinetic parameters and intrinsic clearance depend directly on fu, this assumption may introduce systematic error into the reported Km,u and clearance estimates. Direct determination of Δ8-THC fu in each microsomal system is recommended.
- The kinetic experiments use Δ8-THC concentrations extending to 100 µM, whereas clinically achievable free concentrations are likely considerably lower. The authors should provide a clearer justification for the concentration range and discuss whether the observed substrate inhibition/Hill behavior occurs within pharmacologically relevant exposure ranges.
- Most experiments were performed in triplicate and comparisons were evaluated using two-sided Student’s t-tests. Given the multiple CYP isoforms, concentrations, inhibitors, genotypes, and kinetic parameters evaluated, the manuscript should clarify whether the triplicates represent independent biological experiments or technical replicates and consider appropriate multiple-comparison corrections. The statistical approach for comparing nonlinear kinetic parameters between variants also warrants greater detail.
- The study examines CYP2C9*2, *3, *8 and *9 using recombinant systems, and substantial reductions in intrinsic clearance are reported. However, the manuscript does not directly establish whether these variants alter Δ8-THC metabolism in human hepatocytes or in individuals carrying these alleles. The pharmacogenetic interpretation should therefore be presented as a hypothesis-generating finding rather than evidence sufficient to recommend clinical dose adjustment.
- Metabolic activity from recombinant systems is normalized using relative expression factors determined by Western blotting. The authors should provide more information regarding validation, reproducibility, linearity of the Western blot measurements, and whether differences in enzyme expression, membrane incorporation, or functional activity could influence the calculated relative clearance.
- The manuscript appropriately finds a strong relationship between CYP2C9 activity and intestinal metabolism, whereas the HLM results indicate a more complex hepatic pathway. The title, abstract, and conclusion should consistently distinguish “major intestinal enzyme” from “major enzyme responsible for overall Δ8-THC metabolism.” This distinction is important because the current wording could be interpreted too broadly.
- Three models; Michaelis–Menten, Hill, and substrate inhibition were fitted to the data. The manuscript should state explicitly what statistical criteria were used to select the best-fitting model (e.g., AIC, extra-sum-of-squares F test, residual analysis, or adjusted R²), rather than relying primarily on visual/model fit.
- The limitations section is useful but could be expanded to emphasize the lack of intact-cell, hepatocyte, animal, and human pharmacokinetic validation, potential differences between recombinant CYP systems and native tissues, and the uncertainty surrounding the contribution of untested CYP enzymes. The authors already recognize that additional CYP characterization and clinical studies are necessary.
- The conclusion is somewhat stronger than the experimental evidence supports. The conclusion that CYP2C9 is the primary enzyme involved in intestinal metabolism is well supported, but conclusions concerning overall Δ8-THC disposition and clinical pharmacogenetic consequences should be presented more cautiously.
- The reference list should be updated with the most recent literature on Δ8-THC metabolism, pharmacokinetics, safety, and pharmacogenetics.
- Additional references are needed to support the clinical pharmacogenetic implications.
Overall assessment: I would consider this a technically valuable manuscript with several important but addressable methodological and translational limitations. The strongest revision should focus on tempering the clinical claims, strengthening the statistical analysis, directly addressing the fu assumption, and more clearly separating intestinal CYP2C9 activity from the unresolved hepatic metabolism of Δ8-THC.
Author Response
Response to Reviewer 1
1. The study relies entirely on recombinant CYP-overexpressing microsomes, human liver microsomes (HLM), and human intestinal microsomes (HIM). Although the findings strongly implicate CYP2C9, there are no human pharmacokinetic or clinical genotype–phenotype data to demonstrate that the observed differences in CYP2C9 activity actually translate into altered Δ8-THC exposure in vivo. Therefore, statements regarding dosage adjustment and interindividual pharmacokinetic variability should be moderated.
Response: The statement in the Discussion section has been adjusted with more focus on the impact of the corresponding amino acid substitutions (p. 13, lines 406-407).
- The authors conclude that CYP2C9 is the major enzyme for intestinal 11′-hydroxylation but acknowledge that other enzymes may contribute substantially to hepatic metabolism. Since the hepatic clearance of Δ8-THC is clinically important, screening additional CYP isoforms and/or using selective chemical or antibody inhibition in HLM would substantially strengthen the mechanistic conclusion.
Response: The CYP enzymes screened in this study are the major enzymes that are abundant in the liver and responsible for most drug metabolism. Screening additional CYP isoforms and/or conducting selective chemical or antibody inhibition studies in HLM would be valuable approaches for further identifying the enzymes involved in this biotransformation. However, as the primary organ responsible for xenobiotic metabolism, the liver contains a broad range of phase I drug-metabolizing enzymes, including not only CYP isoforms but other enzyme groups which also utilize NADPH as a cofactor and perform similar metabolic functions as CYPs.1 A comprehensive screening of all possible enzymes is beyond the scope of the present study, but a better sentence (including new references) describing this limitation has been added to the Discussion section of the manuscript (p. 13, lines 397-402).
The unbound fraction of Δ8-THC was not experimentally determined; instead, fu values reported for Δ9-THC were used as surrogates. Because the calculated unbound kinetic parameters and intrinsic clearance depend directly on fu, this assumption may introduce systematic error into the reported Km,u and clearance estimates. Direct determination of Δ8-THC fu in each microsomal system is recommended.
Response: The unbound fractions (fu,inc) of Δ9-THC, 11-OH-Δ9-THC, and CBD in incubation mixtures were previously determined using the tube absorption method in mixtures containing either human liver microsomes (HLM) or microsomes derived from HEK293 cells.2 The reported fu,inc values that were identified in that study were as follows:
Δ9-THC: 0.051 ± 0.033 (HLM) and 0.043 ± 0.012 (HEK293 microsomes)
11-OH-Δ9-THC: 0.094 ± 0.014 (HLM) and 0.078 ± 0.042 (HEK293 microsomes)
CBD: 0.098 ± 0.023 (HLM) and 0.062 ± 0.011 (HEK293 microsomes)
As mentioned in the paper, Δ8-THC and Δ9-THC share very similar chemical structures and biochemical properties, particularly their logP values (7.6 for Δ8-THC and 7.5 for Δ9-THC),3 a parameter strongly associated with the fraction unbound (fu) in vitro.4 In addition, previous studies have shown that cannabidiol (CBD), which has a lower logP (~ 6.0) than either Δ8-THC and Δ9-THC, exhibits a similar unbound fraction to Δ9-THC in vitro, with both Δ9-THC and CBD showing <10% unbound.5 Also, we found that the Simcyp-estimated unbound fractions in the incubation (fu,inc) were also comparable between Δ8-THC and Δ9-THC (data not shown). Therefore, the use of the fu,inc for Δ9-THC as a surrogate for Δ8-THC would likely have very minimal effects on kinetic values, we acknowledge this limitation and this is now better described (with an additional reference) in the Discussion section (p. 14, lines 449-452).
The kinetic experiments use Δ8-THC concentrations extending to 100 µM, whereas clinically achievable free concentrations are likely considerably lower. The authors should provide a clearer justification for the concentration range and discuss whether the observed substrate inhibition/Hill behavior occurs within pharmacologically relevant exposure ranges.
Response: The Δ8-THC concentration range used in the kinetic experiments (up to 100 µM) was selected primarily to capture the full enzyme kinetic profile rather than representing clinically achievable systemic concentrations. A sufficiently broad substrate concentration range, including concentrations above the apparent Km, is necessary to accurately estimate kinetic parameters and distinguish among different kinetic models, particularly when substrate inhibition or Hill-type kinetics are observed.
We agree that the pharmacologically relevant Cmax of Δ8-THC (maximum value < 0.5 µM)6,7 is substantially lower than the highest concentrations used in these in vitro experiments. Therefore, the substrate inhibition or Hill kinetics behavior observed at higher Δ8-THC concentrations may have limited direct relevance to typical systemic exposure in humans. Rather, these kinetic features provide mechanistic information regarding enzyme–substrate interactions and allow more accurate characterization of Δ8-THC metabolism across a broad concentration range. We have added this clarification to the revised manuscript (p. 6, lines 172-173).
- Most experiments were performed in triplicate and comparisons were evaluated using two-sided Student’s t-tests. Given the multiple CYP isoforms, concentrations, inhibitors, genotypes, and kinetic parameters evaluated, the manuscript should clarify whether the triplicates represent independent biological experiments or technical replicates and consider appropriate multiple-comparison corrections. The statistical approach for comparing nonlinear kinetic parameters between variants also warrants greater detail.
Response: As now indicated in the manuscript (p. 6, line 173-174), they are independent biological experiments.
For comparisons between CYP2C9 variants, statistical significance was assessed using one-way ANOVA and Student’s t-test. These methodological details and corresponding explanations have been added to the revised manuscript (p. 7, lines 228–230; p. 12, line 355).
The study examines CYP2C9*2, *3, *8 and *9 using recombinant systems, and substantial reductions in intrinsic clearance are reported. However, the manuscript does not directly establish whether these variants alter Δ8-THC metabolism in human hepatocytes or in individuals carrying these alleles. The pharmacogenetic interpretation should therefore be presented as a hypothesis-generating finding rather than evidence sufficient to recommend clinical dose adjustment.
Response: The corresponding statement has been adjusted with more focus on the impact of the corresponding amino acids substitutions (p. 13, lines 406-407).
Metabolic activity from recombinant systems is normalized using relative expression factors determined by Western blotting. The authors should provide more information regarding validation, reproducibility, linearity of the Western blot measurements, and whether differences in enzyme expression, membrane incorporation, or functional activity could influence the calculated relative clearance.
Response: The use of Western blotting is obviously a well-established technique for expression analysis. Consistent results have been routinely obtained in our laboratory using the same antibodies (typically anti-calnexin and anti-V5-HRP) for multiple overexpressed CYP cell lines. The relative expression factor (i.e., REFs) values between individual variants were within a relatively narrow range (<3-fold) and the signals are not over-exposed suggesting that the Western blot signals were in a linear range. In addition, all microsomal specimens used in this study were prepared simultaneously following the same standardized procedure with the same microsomes used in triplicate experiments, thereby minimizing variability introduced during sample preparation. The reason that the REF values used to correct for differences in protein expression were calculated based on only a single experiment is because a control gene is monitored for each lane of protein, with V5-tag expression normalized to that control gene (i.e., calnexin) before being normalized between variant cell lines. This ratio is always the same for that microsomal prep, relieving the necessity of repeat Western blots.
The manuscript appropriately finds a strong relationship between CYP2C9 activity and intestinal metabolism, whereas the HLM results indicate a more complex hepatic pathway. The title, abstract, and conclusion should consistently distinguish “major intestinal enzyme” from “major enzyme responsible for overall Δ8-THC metabolism.” This distinction is important because the current wording could be interpreted too broadly.
Response: The Significance Statement was misleading and has been modified (p. 2). The rest of the manuscript states only that CYP2C9 is a major enzyme responsible for the intestinal metabolism of Δ8-THC. The statement that CYP2C9 is the “major enzyme responsible for overall Δ8-THC metabolism” does not appear in the manuscript.
Three models; Michaelis–Menten, Hill, and substrate inhibition were fitted to the data. The manuscript should state explicitly what statistical criteria were used to select the best-fitting model (e.g., AIC, extra-sum-of-squares F test, residual analysis, or adjusted R²), rather than relying primarily on visual/model fit.
Response: As indicated above and now written in the manuscript, three independent experiments were performed to characterize all enzyme kinetic parameters. The best-fit kinetic model was selected based on Eadie–Hofstee plots and model comparison analyses performed in GraphPad Prism. These methodological details and corresponding explanations have been added to the revised manuscript (p. 6, lines 177–181).
The limitations section is useful but could be expanded to emphasize the lack of intact-cell, hepatocyte, animal, and human pharmacokinetic validation, potential differences between recombinant CYP systems and native tissues, and the uncertainty surrounding the contribution of untested CYP enzymes. The authors already recognize that additional CYP characterization and clinical studies are necessary.
Response: CYPs are not very well conserved between species, making animal studies not very useful. Studies in hepatocytes are a good idea. Some of the proposed content has been added to the Discussion section (p. 14; lines 465-466).
- The conclusion is somewhat stronger than the experimental evidence supports. The conclusion that CYP2C9 is the primary enzyme involved in intestinal metabolism is well supported, but conclusions concerning overall Δ8-THC disposition and clinical pharmacogenetic consequences should be presented more cautiously. The reference list should be updated with the most recent literature on Δ8-THC metabolism, pharmacokinetics, safety, and pharmacogenetics.
Response: The most recent literature on the metabolism, pharmacokinetics, and safety of Δ8-THC has now been cited; however, pharmacogenetic studies of Δ8-THC still remains very limited. Given the increasing prevalence of Δ8-THC use, greater research attention is expected, particularly regarding the potential impact of genetic variation in drug-metabolizing enzymes on its metabolism and pharmacokinetics. The corresponding sentence within the Discussion section has been adjusted with more focus on the impact of the corresponding amino acids substitutions (p. 13, lines 406-407).
Additional references are needed to support the clinical pharmacogenetic implications.
Response: We have addressed this above.
References
- Rendic S, Guengerich FP. Survey of Human Oxidoreductases and Cytochrome P450 Enzymes Involved in the Metabolism of Xenobiotic and Natural Chemicals. Chem Res Toxicol. 2015;28(1):38-42.
- Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions. Drug Metab Dispos. 2021;49(12):1070-1080.
- Punyamurthula NS, Adelli GR, Gul W, Repka MA, ElSohly MA, Majumdar S. Ocular Disposition of ∆(8)-Tetrahydrocannabinol from Various Topical Ophthalmic Formulations. AAPS PharmSciTech. 2017;18(6):1936-1945.
- Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos. 2002;30(12):1497-1503.
- Nelson KM, Bisson J, Singh G, et al. The Essential Medicinal Chemistry of Cannabidiol (CBD). J Med Chem. 2020;63(21):12137-12155.
- Zamarripa CA, Spindle TR, Schriefer D, et al. A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults. Drug Alcohol Depend. 2025;272:112676.
- Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and Pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6).
Author Response File:
Author Response.docx
Reviewer 2 Report
Comments and Suggestions for AuthorsThe manuscript investigates the role of CYP2C9 in the metabolism of Δ8-tetrahydrocannabinol (Δ8-THC) and its potential implications for pharmacogenetics. This topic is of considerable importance to clinical pharmacology and may also have broader societal relevance, particularly in regions where cannabinoid use is legally permitted. However, the significance and rationale of the present study are not sufficiently established. The authors should strengthen the Introduction by clearly explaining the existing knowledge gap, the clinical relevance of CYP2C9-mediated Δ8-THC metabolism, and how the present study advances the field.
Regarding the sample preparation procedure, the authors used an equal volume of cold acetonitrile (ACN) for protein precipitation. The authors should provide a clear justification for this ratio, as higher organic solvent-to-plasma ratios, commonly two- to three-fold excesses of ACN, are generally used to achieve efficient protein precipitation. The authors should demonstrate that the selected ratio provides adequate protein removal and recovery of Δ8-THC and its metabolites.
The authors also reported that the limited solubility of Δ8-THC restricted the use of higher concentrations in the study. This issue should be addressed more thoroughly. For example, could DMSO or another suitable solvent be considered instead of methanol to improve the solubility of Δ8-THC while maintaining analyte stability and ensuring compatibility with the experimental system? The authors should justify the solvent selected and discuss whether alternative approaches could overcome this limitation.
Finally, the resolution and overall quality of the figures should be improved to ensure that the presented data can be clearly interpreted.
Author Response
Responses to Reviewer 2
1. The authors should strengthen the Introduction by clearly explaining the existing knowledge gap, the clinical relevance of CYP2C9-mediated Δ8-THC metabolism, and how the present study advances the field.
Response: The Introduction has been revised with new references (n=8) added to better highlight the significance and translational relevance of the kinetic data generated in this study (p. 3; lines 58-70; lines 74-87). Specifically, we emphasized that these data will help:
- Characterize the efficiency of Δ8-THC biotransformation to 11-OH-Δ8-THC, which is critical for comprehensively evaluating both the therapeutic potential of Δ8-THC as a smoking cessation aid and its potential risk of unintended drug–drug interactions (DDI).
- Support the further development and refinement of PBPK models, enabling more reliable translational predictions of DDI and informing optimal dosing strategies.
Regarding the sample preparation procedure, the authors used an equal volume of cold acetonitrile (ACN) for protein precipitation. The authors should provide a clear justification for this ratio, as higher organic solvent-to-plasma ratios, commonly two- to three-fold excesses of ACN, are generally used to achieve efficient protein precipitation. The authors should demonstrate that the selected ratio provides adequate protein removal and recovery of Δ8-THC and its metabolites.
Response: The use of an equal volume of ice-cold organic solvent is a commonly employed sample-processing approach for in vitro microsomal CYP assays in both academic and industry settings. Maintaining this standardized procedure therefore facilitates comparison of our results with previously reported in vitro metabolism studies.1 The use of a 1:2 or 1:3 sample-to-ACN ratios is primarily when analyzing plasma samples, which contain substantially higher protein concentrations than the microsomal incubation system used in the present study. Given the relatively low microsomal protein concentration in our in vitro incubations, an equal volume of ACN is sufficient for protein precipitation. Also, protein removal was further facilitated by high-speed centrifugation following the addition of ACN, allowing for efficient separation of precipitated microsomal proteins from the supernatant. We have clarified the sample preparation procedure and the rationale for the selected ACN ratio in the revised manuscript and cited references (p. 5; lines 134-136).
The authors also reported that the limited solubility of Δ8-THC restricted the use of higher concentrations in the study. This issue should be addressed more thoroughly. For example, could DMSO or another suitable solvent be considered instead of methanol to improve the solubility of Δ8-THC while maintaining analyte stability and ensuring compatibility with the experimental system? The authors should justify the solvent selected and discuss whether alternative approaches could overcome this limitation.
Response: DMSO was not selected as the solvent because it has been reported to exert inhibitory effects on CYP enzyme activity even at low concentrations and may therefore interfere with enzyme kinetic measurements. Another organic solvent, acetonitrile, could potentially be considered, whose impact is similar to methanol.2
In the present study, Δ8-THC was obtained commercially as a DEA-exempt reference material supplied at 1 mg/mL in methanol. Therefore, methanol was retained as the solvent to avoid additional solvent exchange and sample manipulation. Similar methanolic Δ8-THC preparations have also been used in previous cannabinoid metabolism studies, allowing greater methodological consistency and facilitating comparison of our kinetic data with previously published results.3
In addition, because Δ8-THC is regulated as a Schedule I controlled substance in the United States, the use of substantially higher concentrations was constrained by both its limited aqueous solubility and the amount/concentration of Δ8-THC that could be practically used under the applicable regulatory conditions.
We have clarified the rationale for solvent selection and acknowledged these limitations in the revised manuscript (p. 5; lines 134-136).
The resolution and overall quality of the figures should be improved to ensure that the presented data can be clearly interpreted.
Response: We have increased the font size and removed unnecessary blank spaces to improve the overall readability and presentation of Supplemental Figures 1 and 2. We checked all the rest of the figures and they are extremely clear. It is possible that the website version for the reviewers was blurry, but the resolution and clarity of our original figures are perfect.
References
- Harper TW, Brassil PJ. Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J. 2008;10(1):200-207.
- Busby WF, Jr., Ackermann JM, Crespi CL. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispos. 1999;27(2):246-249.
- Yabut KCB, Winnie Wen Y, Simon KT, Isoherranen N. CYP2C9, CYP3A and CYP2C19 metabolize Delta9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1). Biochem Pharmacol. 2024;228:116191.
Author Response File:
Author Response.docx
Reviewer 3 Report
Comments and Suggestions for AuthorsThe manuscript addresses an interesting and relevant topic and provides valuable experimental evidence regarding the role of CYP2C9 in the metabolism of Δ8-THC. The experimental approach is generally appropriate and the results are potentially relevant for understanding interindividual variability in Δ8-THC disposition. However, I suggest that the authors address the following points before publication:
- Please clarify the interpretation of the hepatic metabolism data. Although CYP2C9 shows the highest intrinsic clearance among the recombinant enzymes tested, the inhibition experiments in HLM do not support a major contribution of CYP2C9 or CYP2C19. The authors should discuss more explicitly how these apparently discrepant findings affect the conclusion that CYP2C9 is a major hepatic enzyme.
- The correction for the unbound fraction (fu) deserves further discussion. The authors use fu values determined for Δ9-THC as a surrogate because fu for Δ8-THC was not experimentally determined. Since this correction has a substantial impact on the reported Km,u and clearance values, the authors should better justify this assumption and clearly indicate its potential effect on the quantitative conclusions.
- Please be cautious with the clinical interpretation of the CYP2C9 variants. The study demonstrates substantial differences in enzyme activity in recombinant microsomes, but the statement that dosage adjustments may be required in individuals carrying reduced-function alleles appears somewhat premature without clinical pharmacokinetic data. I recommend moderating this conclusion and clearly distinguishing the in vitro findings from their potential clinical implications.
- The statistical and kinetic analysis should be described more transparently. Please provide sufficient information on the number of independent biological replicates, how the best kinetic model was selected, and whether formal statistical comparisons between kinetic parameters were performed. This is particularly important for CYP2C9*8, where the reported 246-fold increase in Km,u has a p-value of 0.051.
- A few inconsistencies and typographical issues should be carefully checked throughout the manuscript. For example, the manuscript alternates between Km and Km,u in the discussion, and some statements concerning increases/decreases in Km or intrinsic clearance appear potentially confusing. A careful revision of the terminology and numerical descriptions would improve clarity.
Author Response
Responses to Reviewer 3
1. Please clarify the interpretation of the hepatic metabolism data. Although CYP2C9 shows the highest intrinsic clearance among the recombinant enzymes tested, the inhibition experiments in HLM do not support a major contribution of CYP2C9 or CYP2C19. The authors should discuss more explicitly how these apparently discrepant findings affect the conclusion that CYP2C9 is a major hepatic enzyme.
Response: Our findings suggest that CYP2C9 plays a major role in the intestinal metabolism of Δ8-THC (not hepatic metabolism), as the Kₘ,u values determined in recombinant CYP2C9 microsomes (0.013 ± 0.0032 µM) and human intestinal microsomes (HIM; 0.0076 ± 0.00067 µM) were comparable. This conclusion is further supported by the substantial inhibition of 11′-hydroxylation observed in HIM in the presence of the CYP2C9-selective inhibitor, sulfaphenazole. In contrast, the marked difference in Kₘ,u values between recombinant CYP2C9 microsomes (0.013 ± 0.0032 µM) and human liver microsomes (HLM; 0.73 ± 0.065 µM) together with the relatively weak inhibition by sulfaphenazole in HLM suggests that CYP2C9 may have a more limited contribution to hepatic Δ8-THC 11′-hydroxylation. As indicated in the manuscript, these findings also indicate that additional hepatic enzymes not evaluated in the present study may contribute to this metabolic pathway.
The correction for the unbound fraction (fu) deserves further discussion. The authors use fu values determined for Δ9-THC as a surrogate because fu for Δ8-THC was not experimentally determined. Since this correction has a substantial impact on the reported Km,u and clearance values, the authors should better justify this assumption and clearly indicate its potential effect on the quantitative conclusions.
Response: Addressed above in response to Reviewer 1 with this limitation now described in the manuscript (p. 14, lines 450-453).
Please be cautious with the clinical interpretation of the CYP2C9 variants. The study demonstrates substantial differences in enzyme activity in recombinant microsomes, but the statement that dosage adjustments may be required in individuals carrying reduced-function alleles appears somewhat premature without clinical pharmacokinetic data. I recommend moderating this conclusion and clearly distinguishing the in vitro findings from their potential clinical implications.
Response: As described above in response to Reviewer 1, the Discussion section (p. 13, lines 402-404) has been revised to ‘…and highlight the need for clinical studies to evaluate the impact of CYP2C9 genetic variants on the pharmacokinetics of Δ8-THC.’
The statistical and kinetic analysis should be described more transparently. Please provide sufficient information on the number of independent biological replicates, how the best kinetic model was selected, and whether formal statistical comparisons between kinetic parameters were performed. This is particularly important for CYP2C9*8, where the reported 246-fold increase in Km,u has a p-value of 0.051.
Response: As described above in response to Reviewer 1, three independent experiments were performed to characterize all enzyme kinetic parameters. The best-fit kinetic model was selected based on Eadie–Hofstee plots and model comparison analyses performed in GraphPad Prism. For comparisons between CYP2C9 variants, statistical significance was assessed using one-way ANOVA and Student’s t-test. These methodological details and corresponding explanations have been added to the revised manuscript (p. 7, lines 228–230; p. 12, line 355).
A few inconsistencies and typographical issues should be carefully checked throughout the manuscript. For example, the manuscript alternates between Km and Km,u in the discussion, and some statements concerning increases/decreases in Km or intrinsic clearance appear potentially confusing. A careful revision of the terminology and numerical descriptions would improve clarity.
Response: There is some confusion – our study established Km,u values corrected for the unbound fraction in the incubation (fu,inc) while most previous studies only reported Km values. Therefore, when comparing our results with values reported in other studies or with Km values for Δ9-THC, equivalent parameters were compared (i.e., Km with Km and Km,u with Km,u).
Author Response File:
Author Response.docx
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsThe manuscript has been improved substantially.